Modafinil as Adjunctive Therapy in Depressed Outpatients

References

• American Psychiatric Association: Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(4 suppl):1–45.
   Google Scholar
• Heninger GR, Charney DS, Sternberg DR: Lithium car-bonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depres-sion. Arch Gen Psychiatry 1983; 40:1335–1342.
   PubMed Web of Science ®Google Scholar
• Schopf J, Bauman P. Lemarchand T, Rey M: Treatment of endogenous depressions resistant to tricyclic antide-pressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study. Pharma-copsychiatry 1989; 22:183–187.
   PubMed Web of Science ®Google Scholar
• Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothy-ronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387–393.
   PubMed Web of Science ®Google Scholar
• Stein G, Bernadt M: Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634–640.
   PubMed Web of Science ®Google Scholar
• Katona CL, Abou-Saleh MT, Harrison DA, Nairoc BA, Edwards DR, Lock T, Burns RA, Robertson MM: Placebo-controlled trial of lithium augmentation of flu-oxetine and lofepramine. Br J Psychiatry 1995; 166: 80–86.
   PubMed Web of Science ®Google Scholar
• Bauman P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Percy M: A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical phar-macokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16:307–314.
   Google Scholar
• Nelson JC: Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61:13–19.
   PubMed Web of Science ®Google Scholar
• Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse K, Kushida CA, Wise MS, Hirshkowitz M, Woodson T: Practice parameters for the treatment of narcolepsy: An update for 2000. Sleep 2001; 24:451–466.
   PubMed Web of Science ®Google Scholar
• Bastuji H, Jouvet M: Successful treatment of idio-pathic hypersomnia and narcolepsy with modafmil. Prog Neuropsychopharmacol Bio Psychiatry 1988; 12:695–700.
   PubMed Web of Science ®Google Scholar
• Broughton RJ, Fleming JAE, George CFP, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narco-lepsy. Neurology 1997; 49:444–451.
   PubMed Web of Science ®Google Scholar
• Arnulf I, Homeyer P. Garma L, Whitelaw WA, Derenne J-P: Modafinil in obstructive sleep apnea-hypopnea syndrome: A pilot study in 6 patients. Respira-tion 1997; 64:159–161.
   PubMed Web of Science ®Google Scholar
• U.S. Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43:88–97.
   Google Scholar
• U.S. Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafmil as a treatment for the excessive daytime somnolence of narcolepsy. Neuro-logy 2000; 54:1166–1175.
   Google Scholar
• Pack Al, Black JE, Schwartz JRL, Matheson JK, for the U.S. Modafinil in Obstructive Sleep Apnea Group: Modafmil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675–1681.
   Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld A, Pollak CP, Nagaraja HN: Efficacy and safety of modafinil (PRO VIGIL®) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179–183.
   PubMed Web of Science ®Google Scholar
• Menza MA, Kaufman KR, Castellanos A: Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61:378–381.
   PubMed Web of Science ®Google Scholar
• DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with Major Depressive Disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1057–1064.
   Google Scholar
• Carroll BJ, Feinberg M, Smouse PE, Rawson SG, Greden JF: The Carroll Rating Scale for depression I. Development, reliability and validation. Br J Psychi-atry 1981; 138:194–200.
   PubMed Web of Science ®Google Scholar
• Nasr SJ, Altman EG, Rodin MB, Jobe TH, Burg B: Correlation of the Hamilton and Carroll Depression Rating Scales: A replication study among psychiatric outpatients. J Clin Psychiatry 1984; 45:167–168.
   PubMedGoogle Scholar
• Guy W. ECDEU assessment manual for psychophar-macology. Washington, DC: National Institute of Men-tal Health, US Department of Health, Education, and Welfare, 1976.
   Google Scholar
• Terzoudi M, Gavrielidou P. Heilakos G, Visviki K, Karageorgio CE: Fatigue in multiple sclerosis; evalua-tion and a new pharmacological approach. Neurology 2000; 54 (Suppl 3):A61–62.
   Google Scholar
• DeBattista C, Lembke A, Solvason B, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psycho-pharmacology 2003; 24:87–90.
   Google Scholar
• Lin JS, Hou Y, Jouvet M: Potential brain neuronal tar-gets for amphetamine-, methylphenidate-, and modafmil-induced wakefulness, evidenced by c-fos immunocy-tochemistry in the cat. Proc Natl Acad Sci USA 1996; 93:14126–14133.
   Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB: Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20:8620–8628.
   PubMed Web of Science ®Google Scholar
• Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C: Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daytime sleepiness asso-ciated with narcolepsy. Sleep Med 2000; 1:231–243.
   PubMed Web of Science ®Google Scholar
• Warot D, Corruble E, Payan C, Weil JS, Puech: Subject-ive effects of modafmil, a new central adrenergic stimu-lant in healthy volunteers: A comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993; 8:201–208.
   Google Scholar
• Jasinski DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psy-chopharmacol 2000; 14:53–60.
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Kovacevic-Ristanovic R: Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narco-lepsy. Clin Neuropharmacol 2000; 23:149–156.
   PubMed Web of Science ®Google Scholar
• Emsellem HA and the US Modafinil Study Group: Effi-cacy and safety profiles of PROVIGIL® (modafinil) maintained during long-term (40 and 88 weeks) treat-ment of excessive daytime sleepiness associated with narcolepsy. Neurology 2000; 54\(suppl 3):A29–30.
   Google Scholar